TITLE

Omalizumab reduced inhaled corticosteroid use and exacerbations in childhood allergic asthma

AUTHOR(S)
Mazer, Bruce
PUB. DATE
January 2002
SOURCE
ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the study 'Treatment of Childhood Asthma With Anti-immunoglobulin E Antibody (Omalizumab),' by H. Milgrom, W. Berger, A. Nayak, et al., published in the August 2001 issue of the 'Pediatrics' journal. Comment on the study.
ACCESSION #
8866204

 

Related Articles

  • The pharmacological basis of anti-IgE therapy. Chang, Tse Wen // Nature Biotechnology;Feb2000, Vol. 18 Issue 2, p157 

    The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II and III human clinical studies. The therapeutic efficacy of this approach is attributable to...

  • Anti-IgE Therapy in Allergic Asthma. Rolinck-Werninghaus, Claudia; Wahn, Ulrich; Hamelmann, Eckard // Current Drug Targets - Inflammation & Allergy;Oct2005, Vol. 4 Issue 5, p551 

    Despite the advanced and increasing understanding of the pathophysiology of asthma and other allergic diseases, current treatment remains unspecific and targets late events within the allergic cascade. Therefore, a novel and promising approach to treat allergic asthma is antagonizing IgE by...

  • Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Lanier, Bob // Allergy & Asthma Proceedings;Mar/Apr2006 Supplement, Vol. 27, pS37 

    As clinical experience with omalizumab increases, questions arise from clinicians that are not answered in the product insert or clinical reports. How does this drug really work? There surely must be more than the simple reduction of free IgE which, in and of itself, causes no disease. Can...

  • IgE, Allergic Diseases, and Omalizumab. DuBuske, L. M. // Current Pharmaceutical Design;Oct2006, Vol. 12 Issue 30, p3929 

    Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms....

  • Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E. Tse Wen Chang // Allergy & Asthma Proceedings;Mar/Apr2006 Supplement, Vol. 27, pS7 

    The development of anti-immunoglobulin E (IgE) antibodies for prophylactic and therapeutic applications in allergic diseases has taken nearly 20 years. Limited usage has been approved for allergic asthma. The usage in other allergic indications is in active development and may take an additional...

  • Mechanisms of action of anti-immunoglobulin E therapy. Soresi, Simona; Togias, Alkis // Allergy & Asthma Proceedings;Mar/Apr2006 Supplement, Vol. 27, pS15 

    The currently approved anti-immunoglobulin E (IgE) agent omalizumab is a humanized monoclonal antibody that recognizes human IgE in the vicinity of its binding sites for high- and low-affinity IgE receptors. Omalizumab binds free IgE and the complexes that are formed are removed by the hepatic...

  • Treatment of asthma with anti-immunoglobulin E monoclonal antibody. Liu, Andrew H. // Allergy & Asthma Proceedings;Mar/Apr2006 Supplement, Vol. 27, pS24 

    Clinical experience with anti-immunoglobulin E monoclonal antibody therapy (i.e., omalizumab) for asthma is maturing. Now several years after U.S. Food and Drug Administration approval and release, more studies of the clinical efficacy and safety of omalizumab have been published. We are gaining...

  • Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Parks, Kevin W.; Casale, Thomas B. // Allergy & Asthma Proceedings;Mar/Apr2006 Supplement, Vol. 27, pS33 

    Despite both efficacy and immunotolerogenic effects, many clinicians still are reluctant to use allergen-specific immunotherapy (SIT) because of the potential for acute allergic reactions. The anti-immunoglobulin E monoclonal antibody, omalizumab, is approved by the U.S. Food and Drug...

  • What do non-eosinophilic asthma and airway remodelling tell us about persistent asthma? Gibson, Peter G. // Thorax;Dec2007, Vol. 62 Issue 12, p1034 

    The author reflects on the study that directs drug discovery programmes and effective treatment for most steps in the eosinophilic asthma pathway in Great Britain. It stated that the list includes interventions that act at discrete levels such as allergen avoidance, allergen immunotherapy, and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics